ENHANCING ONCOLOGY STUDY WITH INTEGRATED KRAS ASSAY COMPANIES AND RAS ASSAYS

from the quickly evolving field of oncology analysis, correct and effective mutation screening is crucial for developing specific therapies. The KRAS products and services Platform plays a pivotal part Within this landscape by supplying complete answers for KRAS mutation profiling and analysis. KRAS mutations, present in around ninety five% of RAS-